Management of lamivudine resistance: An overview

Pietro Lampertico, Mauro Viganó, Massimo Colombo

Research output: Contribution to journalArticlepeer-review


In the nineties, lamivudine (LMV) was the first nucleoside analog to be marketed for the treatment of patients with chronic hepatitis B virus (HBV). Following the advent of LMV, the management of patients with chronic hepatitis B, particularly those with advanced liver disease was markedly improved, with a substantial reduction in the rates of liver-related complications and mortality. In the face of excellent safety profile records of the drug, hepatologists had to face for the first time the issue of high rates of HBV resistance to therapy as the result of years of treatment of large cohorts of patients in the West and East. Initially considered no more than a virological problem, LMV resistance was later recognized to be a relevant clinical issue whose management requires specific therapeutic strategies. New, more active oral analogs have been marketed since, and new agents are to appear in the market scenario in the near future; however, LMV is still the number one prescribed anti-HBV agent worldwide for the treatment of chronic HBV patients, due to its limited cost, excellent safety and well predicted resistance profile.

Original languageEnglish
Pages (from-to)66-80
Number of pages15
JournalHepatitis B Annual
Issue number1
Publication statusPublished - Jan 2008


  • Adefovir
  • Chronic hepatitis B
  • Entecavir
  • Hepatitis B virus (HBV)
  • Lamivudine
  • Lamivudine-resistant HBV strains
  • Resistance
  • Tenofovir
  • YMDD

ASJC Scopus subject areas

  • Hepatology
  • Infectious Diseases


Dive into the research topics of 'Management of lamivudine resistance: An overview'. Together they form a unique fingerprint.

Cite this